Sökning: onr:"swepub:oai:DiVA.org:uu-188005" >
Pasireotide (SOM230...
Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR : results from a phase II study
-
Kvols, Larry K (författare)
-
- Öberg, Kjell E (författare)
- Uppsala universitet,Onkologisk endokrinologi
-
O'Dorisio, Thomas M (författare)
-
visa fler...
-
Mohideen, Pharis (författare)
-
de Herder, Wouter W (författare)
-
Arnold, Rudolf (författare)
-
Hu, Ke (författare)
-
Zhang, Yilong (författare)
-
Hughes, Gareth (författare)
-
Anthony, Lowell (författare)
-
Wiedenmann, Bertram (författare)
-
visa färre...
-
(creator_code:org_t)
- 2012
- 2012
- Engelska.
-
Ingår i: Endocrine-related cancer. - 1479-6821. ; 19:5, s. 657-66
- Relaterad länk:
-
https://urn.kb.se/re...
-
visa fler...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- Pasireotide (SOM230) is a novel multireceptor-targeted somatostatin (sst) analog with high binding affinity for sst receptor subtype 1, 2, 3 (sst(1,2,3)) and sst(5). Because of this binding profile, pasireotide may offer symptom control in patients with neuroendocrine tumors (NETs) and carcinoid syndrome no longer responsive to octreotide LAR. This was a phase II, open-label, multicenter study of pasireotide in patients with advanced NET whose symptoms of carcinoid syndrome (diarrhea/flushing) were inadequately controlled by octreotide LAR. Patients received s.c. pasireotide 150 μg twice daily (bid), escalated to a maximum dose of 1200 μg bid until a clinical response was achieved. Forty-four patients were evaluated for efficacy and 45 for tolerability. Pasireotide 600-900 μg s.c. bid effectively controlled the symptoms of diarrhea and flushing in 27% of patients. Evaluation of tumor response in 23 patients showed 13 with stable disease and ten with progressive disease at study end. The most common drug-related adverse events were nausea (27%), abdominal pain (20%), weight loss (20%), and hyperglycemia (16%) and most were of mild or moderate severity. Pasireotide 600-900 μg s.c. bid was effective and generally well tolerated in controlling the symptoms of carcinoid syndrome in 27% of patients with advanced NET refractory or resistant to octreotide LAR therapy.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Kvols, Larry K
-
Öberg, Kjell E
-
O'Dorisio, Thoma ...
-
Mohideen, Pharis
-
de Herder, Woute ...
-
Arnold, Rudolf
-
visa fler...
-
Hu, Ke
-
Zhang, Yilong
-
Hughes, Gareth
-
Anthony, Lowell
-
Wiedenmann, Bert ...
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Cancer och onkol ...
- Artiklar i publikationen
-
Endocrine-relate ...
- Av lärosätet
-
Uppsala universitet